Eli Lilly and Company

Form 483 issued September 15, 2023 · Indianapolis, Indiana

Inspection
Sep 11 – Sep 15, 2023
Observations
5
Pages
5
FEI number
1819470

In short: On September 15, 2023, FDA issued a Form 483 with 5 observations to Eli Lilly and Company in Indianapolis, Indiana (FEI 1819470) after an inspection that ran Sep 11 – Sep 15, 2023.

What FDA observed

Preview: the opening words of each observation
  1. 01
    FDCA 505-1(f)(3)(A)

    An application holder did not ensure healthcare providers (HCPs) who prescribe the drug are specially certified…

  2. 02
    FDCA 505-1(f)(3)(B)

    An application holder did not ensure pharmacies that dispense the drug are specially certified, as required…

  3. 03
    FDCA 505-1(f)(3)(C)

    An application holder did not ensure health care settings that dispense the drug are certified, as…

  4. 04
    FDCA 505-1(f)(3)(D)

    An application holder did not ensure each patient receiving the drug has evidence or other documentation…

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Eli Lilly and Company?

FDA listed 5 observations on this Form 483. The opening words of each observation are shown on this page.

When was Eli Lilly and Company inspected by FDA?

The inspection ran Sep 11 – Sep 15, 2023, and the Form 483 is dated September 15, 2023.

How do I get the full Form 483 for Eli Lilly and Company?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free